Jim Cramer weighs-in on Valeant Pharmaceuticals' $10 billion acquisition of Salix. While he says investors want to buy Salix on this news, Cramer says the one to go after is Valeant. He explains that he was very impressed by the numbers Valeant put out on Monday and shocked at the level of organic growth the company is experiencing despite having some old drugs in its portfolio. Cramer says it's easy to see why people are taking shares of Valeant higher following this news, but he believes the stock can continue to climb. Even though the stock is at $200, Cramer maintains he feels strongly that Valeant is a buy. Valeant expects the transaction to close in the second quarter.